Rigel Pharmaceuticals (RIGL) Receivables - Net (2013 - 2026)

Rigel Pharmaceuticals' Receivables - Net history runs 13 years deep, the most recent figure standing at $49.9 million for Q1 2026.

• On a quarterly basis, Receivables - Net rose 1564.83% year-over-year to $49.9 million in Q1 2026; TTM through Mar 2026 was $49.9 million, a 1564.83% increase from a year earlier, with the FY2025 full-year figure at $51.8 million, up 24.39% from the prior year.
• Receivables - Net fell to $49.9 million in Q1 2026 per RIGL's latest filing, from $51.8 million in the prior quarter.
• Across five years, Receivables - Net topped out at $51.8 million in Q4 2025 and bottomed at $3.0 million in Q1 2025.
• The 5-year median for Receivables - Net is $28.9 million (2024), against an average of $28.9 million.
• Across the five-year window, Receivables - Net slumped 89.28% in 2022 and jumped 1564.83% in 2026, its largest moves.
• Year by year, Receivables - Net stood at $20.0 million in 2022, then jumped by 52.75% to $30.6 million in 2023, then soared by 36.22% to $41.6 million in 2024, then grew by 24.39% to $51.8 million in 2025, then dropped by 3.51% to $49.9 million in 2026.
• Per Business Quant, the three latest RIGL Receivables - Net figures stand at $49.9 million (Q1 2026), $51.8 million (Q4 2025), and $45.9 million (Q3 2025).